Search results
Results from the WOW.Com Content Network
The percentage of patients affected by side effects like Tardive dyskinesia is significantly high and estimated to be a 20-50% prevalence. [1] [2] These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the ...
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
[4] [19] Both EE and CPA have antigonadotropic effects and act as contraceptives in women by suppressing ovulation. [17] The antigonadotropic effects of EE and CPA also contribute to the antiandrogenic efficacy of the medication by suppressing androgen production by the ovaries. [18]
Possible side effects of nicotine [2] [3] The World Health Organization and other health organisations characterise the probability of experiencing side effects as: [4] [5] Very common, ≥ 1 ⁄ 10; Common (frequent), 1 ⁄ 10 to 1 ⁄ 100; Uncommon (infrequent), 1 ⁄ 100 to 1 ⁄ 1000; Rare, 1 ⁄ 1000 to 1 ⁄ 10000; Very rare, < 1 ⁄ 10000
TrimSpa was a dietary supplement designed for weight loss, marketed by the company Goen Technologies and headed by Alexander Szynalski. [1] The ephedra-based supplement was marketed by TrimSpa to help "stave off hunger", [2] until ephedra was banned from the United States. TrimSpa's parent company, Goen Technologies, filed for bankruptcy ...